Clostridium

If you've had watery diarrhea for days after antibiotics, this test asks whether a toxin-producing C. diff organism is present in your stool. A negative result on a properly collected diarrheal sample makes it unlikely that this is the cause.

A positive result is harder to read. PCR finds the DNA of a toxin gene, not the toxin itself. Some people carry the organism without disease, and that is where most bad decisions around this test begin.

What the Test Actually Detects

PCR stands for polymerase chain reaction. It copies a small stretch of DNA until there is enough to detect.

For this test, the specimen is unformed stool and the usual target is bacterial DNA from tcdB, the gene for toxin B. Some assays also look for tcdA, the toxin A gene, and for binary toxin genes seen in strains such as ribotype 027.

Nothing in your own body makes this DNA. It comes from bacteria living in the large intestine. These bacteria grow without oxygen.

The gap matters. Carrying the toxin gene is not the same as making toxin. The assay cannot tell whether the organism is actively injuring your colon or just present in the background.

How Accurate It Is

For finding toxigenic C. diff DNA, this is one of the better stool tests in medicine. A meta-analysis of 19 studies and 7,392 stool samples found about 90% sensitivity and 96% specificity.

Older toxin enzyme immunoassays can miss many cases. In one pediatric evaluation, toxin immunoassay sensitivity was 35%, while PCR sensitivity was 95%. Other head-to-head studies found that PCR returns more positives than toxin testing or cell cytotoxicity testing and can return a result in under four hours.

So the negative result is the cleaner answer. If your diarrheal stool PCR is negative, you should usually look for another cause.

Why a Positive Result Is Not a Diagnosis

Somewhere between 5% and 20% of hospitalized adults carry toxigenic C. diff without symptoms. In very young children, carriage is common enough that routine testing is discouraged unless other causes have been ruled out.

The clearest evidence came from 1,416 hospitalized adults. People who were PCR-positive but toxin-negative carried less organism, had shorter diarrhea, and had no complications attributable to C. diff. Among people positive on both tests, 7.6% had such complications.

Same gene. Different disease state. That is the test in one line.

The Discordant Result Problem

A toxin-negative result does not always mean you can ignore a positive PCR. Some people have true disease caught early, or toxin levels below what the toxin test can detect.

In 240 PCR-positive, toxin-negative inpatients, fever above 38.5 C, severe disease at baseline, and fulminant colitis predicted complications. In inflammatory bowel disease, a PCR-positive, toxin-negative result often tracked with need to escalate IBD therapy rather than with classic toxin-positive infection.

This is not a good-number, bad-number test. It is evidence that an organism is present. Whether it is hurting you depends on stool consistency, fever, white blood cell count, kidney function, abdominal pain, inflammatory markers, and whether another cause explains the diarrhea.

What Happens When People Treat the Test Instead of the Person

Overdiagnosis is common. When one health system switched from immunoassay to PCR, reported infection rates rose by more than 50% without proof that the underlying disease burden had changed. On multiplex diarrhea panels, where C. diff is tested alongside many other pathogens, up to 64% of people whose follow-up antigen and toxin tests were both negative still received C. diff antibiotics.

The cost is not just wasted medication. Treating colonization can damage the gut bacteria that keep C. diff in check. That can make recurrence more likely later.

A quasi-experimental study compared mostly treated versus mostly untreated PCR-positive, toxin-negative hospitalized adults. Withholding antibiotics in selected toxin-negative patients did not increase 30-day death or short-term diarrhea persistence, though the study could not prove every outcome was identical.

Severe Disease and the Strains That Cause It

When infection is real, outcomes range from mild self-limited diarrhea to pseudomembranous colitis, toxic megacolon, bowel perforation, and death.

Some strains are worse than others. Ribotype 027 carries binary toxin genes and a regulatory defect that can raise toxin output. In 1,144 non-recurrent infections, ribotype 027 roughly doubled the odds of death within 30 days after accounting for age and other illnesses. A seven-hospital study found a similar link with severe outcomes, though clinical severity markers still predicted outcomes better than strain type alone.

Existing illness magnifies the damage. Among 2,016 hospitalized people with ulcerative colitis, C. diff colitis more than doubled five-year death risk. In 22,952 cardiac surgery patients, those who developed C. diff in the hospital had lower three-year survival than matched patients without it, along with more kidney failure and bloodstream infection.

A Different Result on Microbiome Panels

Some stool panels report Clostridium species, Clostridia, or Clostridium sensu stricto instead of C. diff toxin genes. That is a different measurement.

The taxonomy is messy because C. difficile was renamed Clostridioides difficile, while many microbiome panels still report broader Clostridium-related groups. These groups include organisms with opposite effects.

Some Clostridia make butyrate. Butyrate is a small fat molecule that colon cells use as fuel. Other species, such as Clostridium perfringens in the small intestine, can behave more like disruptors.

Research cohorts point in both directions. In solid organ transplant recipients, several specific Clostridium species were linked with higher all-cause mortality. In stage I to III colorectal cancer, higher baseline abundance of the order Clostridiales was linked with better disease-free survival.

That is why a genus-level Clostridium number should not be read as more is better or worse. No lab has validated a clinical reference range for it, and different platforms can give different abundance estimates on the same sample. Treat it as exploratory context, not a diagnosis.

When Results Can Be Misleading

• Formed stool: this test was validated for unformed, diarrheal stool. A solid sample mostly tests for carriage, not disease.
• Recent treatment: toxin-gene DNA can persist after symptoms resolve. A positive PCR after treatment does not prove the infection is still active.
• PCR without toxin testing: PCR tells you the toxin gene is present. A toxin A/B immunoassay or cell cytotoxicity test asks whether free toxin is detectable in the stool.
• Cycle threshold: a lower cycle threshold often means more bacterial DNA and a higher chance of toxin positivity, but the ranges overlap. It cannot decide treatment by itself.
• Multiplex diarrhea panels: when C. diff is bundled into broad pathogen panels, pretest probability is often lower. Positives need more caution.
• Genus-level microbiome panels: a Clostridium species abundance result is not a C. diff toxin-gene result. It is exploratory and platform-dependent.

What to Do With an Unexpected Result

If your PCR is positive and you have active watery diarrhea, the next question is whether toxin is present. A toxin A/B enzyme immunoassay helps separate active toxin production from carriage. Toxin-positive with compatible symptoms strongly supports active infection and treatment.

Toxin-negative with mild symptoms often points toward watchful waiting rather than antibiotics. Toxin-negative with fever, a rising white blood cell count, rising creatinine, severe abdominal pain, ileus, or worsening colitis is different. That pattern needs urgent medical evaluation.

If PCR is negative and diarrhea continues, the result is a redirect. A multiplex gastrointestinal panel can find other causes. In a pediatric and young-adult study, a broad panel found an alternate pathogen in 29% of episodes where only C. diff testing had been ordered; norovirus was one common miss. Calprotectin can point toward inflammatory bowel disease. Breath testing can help when bacterial overgrowth is the question.

A gastroenterologist is the right next stop if diarrhea runs for weeks, if there is blood, if you are losing weight, or if pain and fever are escalating.

If you are looking at a genus-level Clostridium number on a microbiome panel with no symptoms, pair it with the rest of the panel and with gut inflammation markers. Do not act on the single number.

Retesting, and When Repeating Is Worth It

For C. diff, this is an episode test, not a trend test. Retesting during the same illness adds little, and repeat testing after successful treatment can stay positive even when the infection is gone.

Test once at the start of a compatible diarrheal illness. Use symptoms and toxin testing to decide what the positive means. Retest only if a new diarrheal episode begins after a symptom-free interval.

Recurrence is common enough to plan for. After a first infection, about one in four people have at least one recurrence, and the odds climb with each further episode. In a phase 3 trial of adults who already had recurrent infection, recurrence within eight weeks was 40% on placebo after antibiotic treatment and 12% after oral purified spores.

Genus-level Clostridium on a microbiome panel is different. If you are tracking a broad gut intervention, use the same lab and look at the whole community pattern over time. A single Clostridium abundance number is not a clinical target.